Primary plasma cell leukemia: A retrospective multicenter study of 73 patients

Annals of Oncology

Volumn 22, Issue 7, 2011, Pages 1628-1635

  Pagano, L ^a   Valentini, C G ^a   de Stefano, V ^a   Venditti, A ^b   Visani, G ^c   Petrucci, M T ^d   Candoni, A ^e   Specchia, G ^f   Visco, C ^g   Pogliani, E M ^h   Ferrara, F ⁱ   Galieni, P ^j   Gozzetti, A ^k   Fianchi, L ^a   de Muro, M ^l   Leone, G ^a   Musto, P ^m   Pulsoni, A ^d  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAN SALVATORE HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF UDINE   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g SAN BORTOLO HOSPITAL   (Italy)

^h SAN GERARDO HOSPITAL   (Italy)

ⁱ CARDARELLI HOSPITAL   (Italy)

^j Ascoli Piceno Hospital   (Italy)

^k UNIVERSITY OF SIENA   (Italy)

^l UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^m REFERRAL CANCER CENTER OF BASILICATA   (Italy)

more..

Author keywords

Bortezomib; Chemotherapy; Hematopoietic stem cell transplantation; Primary plasma cell leukemia; Prognostic factors; Thalidomide

Indexed keywords

ALBUMIN; ALKYLATING AGENT; BETA 2 MICROGLOBULIN; BORTEZOMIB; CALCIUM; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; MELPHALAN; METHOTREXATE; STEROID; THALIDOMIDE; THIOTEPA; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN DISEASE; CANCER LOCALIZATION; CANCER MORTALITY; CAUSE OF DEATH; CLINICAL FEATURE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; ETHNIC GROUP; FEMALE; HEPATOMEGALY; HUMAN; HYPOALBUMINEMIA; INTRAABDOMINAL DRUG ADMINISTRATION; ISCHEMIC COLITIS; ITALIAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OSTEOLYSIS; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; PRIMARY PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SEPSIS; SPLENOMEGALY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79959751913     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq646     Document Type: Article

References (30)

1. Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med 1974; 133: 813.
2. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma orking Group. Br J Haematol 2003; 121: 749-757.
3. Jimenez-Zepeda VH, Domínguez VJ. Plasma cell leukemia: a rare condition. Ann Hematol 2006; 85(4): 263-267.
4. Ramsingh G, Mehan P, Luo J et al. Primary plasma cell leukemia: a surveillance, epidemiology, and end results database analysis between 1973 and 2004. Cancer 2009; 115(24): 734-5739.
5. Kyle RA, Therneau TM, Rajkumar SV et al. Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. Cancer 2004; 101(11): 2667-2674.
6. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med 1987; 83(6): 1062-1068.
7. Bernasconi C, Castelli G, Pagnucco G, Brusamolino E. Plasma cell leukemia: a report on 15 patients. Eur J Haematol Suppl 1989; 51: 76-83.
8. Garcia-Sanz R, Orfao A, Gonzalez M et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999; 93(3): 1032-037.
9. Costello R, Sainty D, Bouabdallah R et al. Primary plasma cell leukemia: a report of 18 cases. Leuk Res 2001; 25(2): 103-107.
10. Vela-Ojeda J, Garcia-Rouiz Esparza MA, Rosas-Cabral A et al. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol 2002; 81: 362-367.
11. Tiedemann RE, Gonzalez-Paz N, Kyle RA et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008; 22: 1044-1052.
12. Colovic M, Jankovic G, Suvajdzic N et al. Thirty patients with primary plasma cell leukemia: a single center experience. Med Oncol 2008; 25: 154-160.
13. Peijing Q, Yan X, Yafei W et al. A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China. Acta Haematol 2009; 121: 47-51.
14. Jimenez-Zepeda VH, Dominguez-Martinez VJ. Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. Int J Hematol 2009; 89: 259-268.
15. Hayman SR, Fonseca R. Plasma cell leukemia. Curr Treat Options Oncol 2001; 2(3): 205-216.
16. Saccaro S, Fonseca R, Veillon DM et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogenic stem-cell transplantation and review of the iterature. Am J Hematol 2005; 78(4): 288-294.
17. BladéJ, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102(5): 1115-1123.
18. Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20(9): 1467-1473.
19. Fonseca R, Bergsagel PL, Drach J et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210-2221.
20. Anderson KC, Kyle RA, Rajkumar SV et al. on behalf of the ASHTM/FDA Panel on Clinical Endpoints in Multiple Myeloma. Clinically relevant end points and new drug pprovals for myeloma. Leukemia 2008; 22: 231-239.
21. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23(15): 3412-3420.
22. Avet-Loiseau H, Daviet A, Brigaudeau C et al. Cytogenetic, interphase, and multicolour fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Francxais de Cytogénétique Hématologique. Blood 2001; 97: 822-825.
23. Lloveras E, Granada I, Zamora L et al. Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukemia. Cancer Genet ytogenet 2004; 148(1): 71-76.
24. Petrucci MT, Martini M, Levi A et al. Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk Lymphoma 2007; 48(1): 80-182.
25. Musto P, Pietrantuono G, Guariglia R et al. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res 2008; 32(10): 1637-1638.
26. Musto P, Rossini F, Gay F et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007; 109(11): 2285-2290.
27. Finnengan DPJ, Kettle P, Drake M et al. Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma 2006; 47(8): 1670-1673.
28. Al-Nawakil C, Tamburini J, Bardet V et al. Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leuk ymphoma 2008; 49(10): 2012-2014.
29. Johnson MR, Del Carpio-Jayo D, Lin P et al. Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and tem cell transplantation. Ann Diagn Pathol 2006; 10(5): 263-268.
30. Drake MB, Iacobelli S, van Biezen A et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica 2010; 95(5): 804-809.